AGL Share PerformanceMore
|52 week high||80.00 15/06/17|
|52 week low||32.27 07/09/17|
|52 week change||0.50 (0.99%)|
|4 week volume||2,746,792 30/04/18|
Media for (AGL)
Latest News« previous» nextMore
14/05/2018 - 07:00 RNS
RNS Number: 8891N Angle PLC 14 May 2018 For immediate release 14 May 2018 ANGLE plc ("the Company") LEADING NHS PROSTATE CANCER SURGEON APPOINTED AS SCIENTIFIC ADVISOR ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointment of Mr Greg L Shaw as a Scientific Adv...
03/05/2018 - 07:00 RNS
RNS Number: 9525M Angle PLC 03 May 2018 For immediate release 3 May 2018 ANGLE plc ("the Company") ANGLE AND QIAGEN PRESENT POSTER AT LEADING CANCER CONFERENCE DEMONSTRATING UTILITY OF ANGLE'S PARSORTIX SYSTEM IN CONJUNCTION WITH QIAGEN'S ADNATEST ASSAY First joint marketing material relea...
19/04/2018 - 11:10 StockMarketWire
finnCap today reaffirms its corporate investment rating on Angle PLC (LON:AGL) and set its price target at 108p. Broker F...
19/04/2018 - 08:54 StockMarketWire
Liquid biopsy Angle revealed Thursday the results of a recent study demonstrated a workflow for the recovery and cultu...
19/04/2018 - 07:00 RNS
RNS Number: 3941L Angle PLC 19 April 2018 For immediate release 19 April 2018 ANGLE plc ("the Company") ANGLE'S PARSORTIX SYSTEM SHOWCASED IN MULTIPLE PRESENTATIONS AT LEADING CANCER CONFERENCE AACR 2018 Customers and collaborators publish more successful research with ANGLE's Parsortix circulating tumor cell (CT...
19/04/2018 - 07:00 RNS
RNS Number: 3936L Angle PLC 19 April 2018 For immediate release 19 April 2018 ANGLE plc ("the Company") BREAKTHROUGH RESEARCH DEMONSTRATES PARSORTIX WORKFLOW FOR CULTURING CIRCULATING TUMOR CELLS FOR IN-VITRO DRUG TESTING Unique capabilities of ANGLE's Parsortix system address a key aim of precision m...
05/04/2018 - 09:37 StockMarketWire
Angle reported Thursday that the first patient was enrolled into its clinical study for metastatic breast cancer.
05/04/2018 - 07:00 RNS
RNS Number: 8764J Angle PLC 05 April 2018 For immediate release 5 April 2018 ANGLE plc ("the Company") FIRST PATIENT ENROLLED IN CLINICAL STUDY TO SUPPORT FDA CLEARANCE OF THE PARSORTIX SYSTEM FDA clearance would provide worldwide differentiation for the Parsortix system in the multi-billion dollar liquid biopsy market A...
|Dividend yield||0 %|
Latest discussion posts More
“With this share. Seems to hold immense potential and under 120 .million shares in issue. Regular stream of ?good news? but no major upward shift in price. I have repeatedly ...”▼
“Mmm. Rarely seems to be reflected in the SP. Still the latest target seems to be around 100p. Just gotta hold in there.”▼
“Collaborations coming together.”▼
Codes & Symbols
|Symbols||AGL, LSE:AGL, AGL.L, AGL:LN, LON:AGL, XLON:AGL|